AAAAAA

   
Results: 1-10 |
Results: 10
THE COST OF REACHING NATIONAL-CHOLESTEROL-EDUCATION-PROGRAM (NCEP) GOALS IN HYPERCHOLESTEROLEMIC PATIENTS - A COMPARISON OF ATORVASTATIN, SIMVASTATIN, LOVASTATIN AND FLUVASTATIN
Authors: KOREN MJ SMITH DG HUNNINGHAKE DB DAVIDSON MH MCKENNEY JM WEISS SR SCHROTT HG HENLEY RW TRESH P MCLAIN RW BAKKERARKEMA RG BLACK DM
Citation: Mj. Koren et al., THE COST OF REACHING NATIONAL-CHOLESTEROL-EDUCATION-PROGRAM (NCEP) GOALS IN HYPERCHOLESTEROLEMIC PATIENTS - A COMPARISON OF ATORVASTATIN, SIMVASTATIN, LOVASTATIN AND FLUVASTATIN, PharmacoEconomics, 14(1), 1998, pp. 59-70
A BRIEF PAPER OF THE EFFICACY AND SAFETY OF ATORVASTATIN IN EARLY CLINICAL-TRIALS
Authors: BAKKERARKEMA RG BEST J FAYYAD R HEINONEN TM MARAIS AD NAWROCKI JW BLACK DM
Citation: Rg. Bakkerarkema et al., A BRIEF PAPER OF THE EFFICACY AND SAFETY OF ATORVASTATIN IN EARLY CLINICAL-TRIALS, Perfusion, 11(2), 1998, pp. 79-86
TREATING PATIENTS WITH DOCUMENTED ATHEROSCLEROSIS TO NATIONAL CHOLESTEROL EDUCATION PROGRAM-RECOMMENDED LOW-DENSITY-LIPOPROTEIN CHOLESTEROLGOALS WITH ATORVASTATIN, FLUVASTATIN, LOVASTATIN AND SIMVASTATIN
Authors: BROWN AS BAKKERARKEMA RG YELLEN L HENLEY RW GUTHRIE R CAMPBELL CF KOREN M WOO W MCLAIN R
Citation: As. Brown et al., TREATING PATIENTS WITH DOCUMENTED ATHEROSCLEROSIS TO NATIONAL CHOLESTEROL EDUCATION PROGRAM-RECOMMENDED LOW-DENSITY-LIPOPROTEIN CHOLESTEROLGOALS WITH ATORVASTATIN, FLUVASTATIN, LOVASTATIN AND SIMVASTATIN, Journal of the American College of Cardiology, 32(3), 1998, pp. 665-672
TREATING TO MEET NCEP-RECOMMENDED LDL CHOLESTEROL CONCENTRATIONS WITHATORVASTATIN, FLUVASTATIN, LOVASTATIN, OR SIMVASTATIN IN PATIENTS WITH RISK-FACTORS FOR CORONARY HEART-DISEASE
Authors: HUNNINGHAKE D BAKKERARKEMA RG WIGAND JP DREHOBL M SCHROTT H EARLY JL ABDALLAH P MCBRIDE S BLACK DM
Citation: D. Hunninghake et al., TREATING TO MEET NCEP-RECOMMENDED LDL CHOLESTEROL CONCENTRATIONS WITHATORVASTATIN, FLUVASTATIN, LOVASTATIN, OR SIMVASTATIN IN PATIENTS WITH RISK-FACTORS FOR CORONARY HEART-DISEASE, Journal of family practice, 47(5), 1998, pp. 349-356
AN OVERVIEW OF THE CLINICAL SAFETY PROFILE OF ATORVASTATIN (LIPITOR),A NEW HMG-COA REDUCTASE INHIBITOR
Authors: BLACK DM BAKKERARKEMA RG NAWROCKI JW
Citation: Dm. Black et al., AN OVERVIEW OF THE CLINICAL SAFETY PROFILE OF ATORVASTATIN (LIPITOR),A NEW HMG-COA REDUCTASE INHIBITOR, Archives of internal medicine, 158(6), 1998, pp. 577-584
VARIATIONS IN COSTS AMONG PAYERS IN TREATMENT WITH HMG-COA REDUCTASE INHIBITOR THERAPY TO ACHIEVE TARGET LIPID-LEVELS
Authors: SMITH DG BAKKERARKEMA RG MCLAIN RW BLACK DM
Citation: Dg. Smith et al., VARIATIONS IN COSTS AMONG PAYERS IN TREATMENT WITH HMG-COA REDUCTASE INHIBITOR THERAPY TO ACHIEVE TARGET LIPID-LEVELS, American journal of managed care, 3(10), 1997, pp. 10-10
2-YEAR COMPARISON OF SAFETY AND EFFICACY OF ATORVASTATIN AND LOVASTATIN
Authors: BAKKERARKEMA RG SHURZINSKE L DAVIDSON M MCKENNEY J STEIN E SCHROTT H BLACK DM
Citation: Rg. Bakkerarkema et al., 2-YEAR COMPARISON OF SAFETY AND EFFICACY OF ATORVASTATIN AND LOVASTATIN, Atherosclerosis, 134(1-2), 1997, pp. 119-119
AN OVERVIEW OF THE CLINICAL SAFETY PROFILE OF ATORVASTATIN A NEW, MORE EFFECTIVE HMG-COA REDUCTASE INHIBITOR
Authors: BAKKERARKEMA RG BLACK DM NAWROCKI JW
Citation: Rg. Bakkerarkema et al., AN OVERVIEW OF THE CLINICAL SAFETY PROFILE OF ATORVASTATIN A NEW, MORE EFFECTIVE HMG-COA REDUCTASE INHIBITOR, Atherosclerosis, 134(1-2), 1997, pp. 119-119
A BRIEF REVIEW PAPER OF THE EFFICACY AND SAFETY OF ATORVASTATIN IN EARLY CLINICAL-TRIALS
Authors: BAKKERARKEMA RG BEST J FAYYAD R HEINONEN TM MARAIS AD NAWROCKI JW BLACK DM
Citation: Rg. Bakkerarkema et al., A BRIEF REVIEW PAPER OF THE EFFICACY AND SAFETY OF ATORVASTATIN IN EARLY CLINICAL-TRIALS, Atherosclerosis, 131(1), 1997, pp. 17-23
EFFICACY AND SAFETY OF A NEW HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN, IN PATIENTS WITH HYPERTRIGLYCERIDEMIA
Authors: BAKKERARKEMA RG DAVIDSON MH GOLDSTEIN RJ DAVIGNON J ISAACSOHN JL WEISS SR KEILSON LM BROWN WV MILLER VT SHURZINSKE LJ BLACK DM
Citation: Rg. Bakkerarkema et al., EFFICACY AND SAFETY OF A NEW HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN, IN PATIENTS WITH HYPERTRIGLYCERIDEMIA, JAMA, the journal of the American Medical Association, 275(2), 1996, pp. 128-133
Risultati: 1-10 |